Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”
A discussion of ethics concerns in psychiatric genetics focusing on predictive genetic testing, psychosocial consequences for patients, effects on family and communities, and the ethics of some emerging technologies.
Karen Uhlenhuth, Angira Patel, MD, and John Lantos, MD
A statin drug will not give a 10-year-old a high level of energy, the freedom to interact with peers without fear of being bullied, or a generally happy outlook on life.